Navidea Biopharmaceuticals (NYSE:NAVB) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a research note released on Monday morning. The firm issued a sell rating on the stock. Navidea Biopharmaceuticals Stock Performance Shares of NAVB opened at $0.04 on Monday. The company has a 50-day simple moving average of $0.04 and a 200-day simple […]

Related Keywords

,Therapeutic Development Programs ,Navidea Biopharmaceuticals Inc ,Navidea Biopharmaceuticals Company Profile ,Navidea Biopharmaceuticals ,Free Report ,Get Free Report ,Diagnostic Substances ,Therapeutic Development ,Navidea Biopharmaceuticals Daily ,Nyse Navb ,Navb ,Medical ,Initiated Coverage ,Stocknews Com ,